News
HGEN
--
0.00%
--
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
BURLINGAME, Calif., January 18, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication ...
Business Wire · 1d ago
Humanigen Aligns With FDA On Potential Registration Phase 3 Study For Lenzilumab With CAR-T
Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ today outlined the next
Benzinga · 01/10 10:55
Why 2022 Holds Hope for Humanigen Stock, According to This Analyst
It has been a rough 12 months for Humanigen (HGEN), with shares down by 80%. Investors will be hoping 2022 will provide more joy; the company’s prospective Covid-19 treatment could go some way to changing sentiment around this beaten down name. On Wednesda...
TipRanks · 01/06 20:11
Humanigen expects data from phase 2/3 study of lenzilumab by early Q2 following enrollment
Humanigen (NASDAQ:HGEN) achieved target enrollment in a phase 2/3 ACTIV-5/BET-B study of its lead drug candidate lenzilumab to treat COVID-19. The company said the ACTIV-5/BET-B study was designed to align with
Seekingalpha · 01/05 12:57
BRIEF-Humanigen Announces Target Enrollment in Phase 2/3 Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
reuters.com · 01/05 11:27
BRIEF-Humanigen Inc - Met With Senior Staff Of FDA In A Type B Meeting Regarding Lenzilumab For The Treatment Of COVID-19
reuters.com · 01/05 11:25
Humanigen says lenzilumab response in hospitalized COVID-19 patients correlates with CRP levels
Humanigen (NASDAQ:HGEN) announces that detail results of an analysis of C-Reactive Protein (CRP) levels from the LIVE-AIR Phase 3 study are available on medRxiv. The LIVE-AIR study enrolled 520 patients who
Seekingalpha · 01/03 11:27
Humanigen Announced Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
Humanigen, Inc.
Benzinga · 01/03 10:56
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
Benzinga · 12/21/2021 10:25
After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News
Humanigen Inc (NASDAQ: HGEN) announced that The Lancet Respiratory Medicine 
Benzinga · 12/02/2021 12:06
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
BURLINGAME, Calif., December 01, 2021--Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
Business Wire · 12/01/2021 23:45
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
BURLINGAME, Calif., December 01, 2021--The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
Business Wire · 12/01/2021 23:30
20 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results were down year over year.
Benzinga · 11/29/2021 11:58
Humanigen Announces Abstracts Accepted For The British Thoracic Society Winter Meeting 2021
Abstract #S48 describes top-line results from the Humanigen Phase 3 LIVE-AIR study in hospitalized COVID-19 patients, which reveal a 54% relative improvement in the likelihood of survival without invasive
Benzinga · 11/22/2021 11:33
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
BURLINGAME, Calif., November 16, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that its presentation time at the...
Business Wire · 11/16/2021 12:47
University Of Notre Dame Du Lac Buys Bath & Body Works Inc, Pegasystems Inc, Intuit Inc, ...
GuruFocus News · 11/15/2021 14:39
Humanigen EPS misses by $0.14, beats on revenue
Humanigen (NASDAQ:HGEN): Q3 GAAP EPS of -$1.12 misses by $0.14. Revenue of $1.04M beats by $0.97M. Press Release As of September 30, 2021, the company had cash and cash equivalents
Seekingalpha · 11/12/2021 21:06
Humanigen Q3 Sales $1.04M
Humanigen (NASDAQ:HGEN) reported $1.04 million in sales this quarter.
Benzinga · 11/12/2021 21:01
Humanigen Q3 Net Loss Widens Compared With Year-Ago Quarter
MT Newswires · 11/12/2021 16:19
Humanigen Announces Clinical Trial Collaboration To Evaluate Lenzilumab In Acute Graft Versus Host Disease
Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The "Risk Adapted Therapy
Benzinga · 11/11/2021 11:31
Webull provides a variety of real-time HGEN stock news. You can receive the latest news about Humanigen through multiple platforms. This information may help you make smarter investment decisions.
About HGEN
Humanigen, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing immuno-oncology and immunology monoclonal antibodies. The Company’s Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily for chronic conditions. It is focused on development of lead product candidate lenzilumab, a Humaneered anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody. Lenzilumab is a monoclonal antibody designed to target and neutralize human GM-CSF and prevents outcomes related to COVID-19. It is also developing lenzilumab as a treatment for autoimmune and other inflammatory conditions, including eosinophilic asthma, rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), atopic dermatitis (AD) and systemic lupus erythematosus (SLE).